Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
M648657-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$350.90
|
|
|
M648657-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$600.90
|
|
|
M648657-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,250.90
|
|
| Specifications & Purity | ≥99% |
|---|---|
| Biochemical and Physiological Mechanisms | MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase ( MPO ). MPO-IN-1 has IC 50 s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits MPO activity in an acute mouse mo |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase ( MPO ). MPO-IN-1 has IC 50 s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits MPO activity in an acute mouse model of inflammation In Vivo MPO-IN-1 (compound 2) (5 and 90 mg/kg; p.o.; four hours post-Zymosan A administration) significantly reduces MPO activity in a mouse peritonitis model of acute inflammation . Mouse pharmacokinetic parameter of MPO-IN-1 . Dose V ss (L/kg) T 1/2 (h) AUC inf (nM•h) p.o. C max (nM) p.o. PPB (%) F (%) 1/10 mg/kg i.v./p.o. 9.8 2.6 2486 502 99.6 61 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J mice (mouse peritonitis model of acute inflammation) Dosage: 5 and 90 mg/kg Administration: p.o. (four hours post-Zymosan A administration) Result: Resulted in a ~50% reduction in the MPO activity at 90 mg/kg. Form:Solid IC50& Target:2.6 μM (in plasma MPO assay),0.12 μM (in fluorescent MPO peroxidation assay) |
| Smiles | ClC1=C(C(C2=CC3=C(C=CN3)C=C2)=CN4C5=CC=C(CN(C)C)C=C5)C4=NC=C1 |
|---|---|
| Molecular Weight | 400.90 |
| Solubility | DMSO : 200 mg/mL (498.88 mM; ultrasonic and warming and heat to 60°C) |
|---|